Oral Forodesine (Bcx-1777) Is Clinically Active in Refractory Cutaneous T-Cell Lymphoma: Results of a Phase I/II Study.

@inproceedings{Duvic2006OralF,
  title={Oral Forodesine (Bcx-1777) Is Clinically Active in Refractory Cutaneous T-Cell Lymphoma: Results of a Phase I/II Study.},
  author={Madeleine Duvic and Andr{\'e}s Forero-Torres and Francine M. Foss and Elsie A. Olsen and Youn H Kim},
  year={2006}
}
  • Madeleine Duvic, Andrés Forero-Torres, +2 authors Youn H Kim
  • Published 2006
  • Medicine
  • Background: Forodesine is a potent, rationally designed purine nucleoside phosphorylase (PNP) inhibitor that is orally bioavailable. IV forodesine has shown clinical activity in patients with cutaneous T-cell lymphoma (CTCL). The objective of this phase I/II study was to evaluate the safety, PK profile, and efficacy of oral forodesine in patients with refractory CTCL. Methods: An open-label dose-escalation study of fordesine, 40 to 320 mg/m 2 qd for 4 weeks, was undertaken to evaluate the… CONTINUE READING

    Create an AI-powered research feed to stay up to date with new papers like this posted to ArXiv

    Topics from this paper.

    Citations

    Publications citing this paper.
    SHOWING 1-9 OF 9 CITATIONS

    Panoptic clinical review of the current and future treatment of relapsed/refractory T-cell lymphomas: Cutaneous T-cell lymphomas.

    VIEW 6 EXCERPTS
    CITES RESULTS & BACKGROUND
    HIGHLY INFLUENCED

    Forodesine: review of preclinical and clinical data.

    VIEW 10 EXCERPTS
    CITES BACKGROUND
    HIGHLY INFLUENCED

    Cutaneous T cell Lymphoma: an Update on Pathogenesis and Systemic Therapy

    VIEW 1 EXCERPT
    CITES RESULTS

    New strategies in the treatment of T-cell lymphoma.

    • H Miles Prince
    • Medicine
    • Clinical advances in hematology & oncology : H&O
    • 2008